Please assess the completion status of the following clinical trial:

Trial Title: Phase II Combination Stem Cell Therapy for the Treatment of Severe Leg Ischemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females older than 18 years of age.~* Limb ischemia with ABI of \< 0.7 in the index lower extremity in two consecutive examinations done at least 1 week apart.~* Limb ischemia with resting ischemic pain and/or claudication at 100 meters and/or non-healing ulcers.~* Claudication~* Patients not considered candidates for surgical or percutaneous revascularization, due to poor target vessels, inability to cross total occlusions, or a morbidity which precludes general anesthesia.~Exclusion Criteria:~* Inability to provide informed consent.~* Previous angiogenic therapy.~* Known sensitivity to gentamycin and/or amphotericin B.~* Use or expected use of antineoplastic drugs.~* Any illness, which might affect the patient's survival after enrollment in the protocol.~* Any illness or significant laboratory abnormality, which in the investigator's judgment will interfere with the patient's ability to comply with the protocol, compromise the patient's safety, or interfere with the interpretation of the study results.~* No evidence of acute infection~* WBC \> 15000.~* WBC \< 4000.~* Serum Creatinine \> 3.0 mg/dL in patients who are not in hemodialysis.~* Pregnant women or women planning to become pregnant or unwilling to use appropriate birth control methods before and 2 months after cell infusion.~* Recent myocardial infarction within 3 months prior to screening.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MESENDO (Type: EXPERIMENTAL): All subjects will receive active treatment in a blinded fashion in the left or right lower limb. The opposite lower limb will receive placebo.
- placebo (Type: PLACEBO_COMPARATOR): All subjects will receive placebo injections in a blinded fashion in the left or right lower limb. The opposite lower limb will receive active stem cell infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).